Traws Pharma, Inc.
TRAWTraws Pharma, Inc. in brief
Traws Pharma, Inc. is a listed company in the Biotechnology industry, based in Newtown, Pennsylvania, USA. Its market value was $5 M on 30 October 2026, which makes it the 27,017th largest listed company in the world and the 4,417th largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net profit of $9 M. It employs about 7 people. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol TRAW (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Traws Pharma, Inc.
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.
On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger with Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID-19 and other infectious diseases. Prior to the Merger, the focus of our business was the discovery and development of novel products for patients with cancer. After completion of the Merger, the focus of our business expanded to include the development of novel therapies to target critical threats to human health in respiratory viral diseases. Following the Merger, we have four clinical programs: (i) tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza; (ii) ratutrelvir, an inhibitor of the main protease (also known as 3CL protease) of the SAR-CoV-2 virus, the causative agent in COVID-19; (iii) narazaciclib (ON 123300), a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and (iv) rigosertib, administered alone or in combination for investigation in various cancers. Each of these programs is discussed in additional detail, below.
From the company's annual report filed with the US SEC: read the report
Traws Pharma, Inc. timeline
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔Initial public offering as Onconova Therapeutics IncFinal prospectus filed with the SEC on 25 July 2013; shares registered for exchange trading on 23 July 2013.
- 2024
- ✎Renamed Traws Pharma, Inc.Formerly Onconova Therapeutics Inc.
- 2025
- 💰Record revenue of $3 millionFY2025, the highest of the 8 years on record.
Events of Traws Pharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,321 (Oct 2026) · #4,418 (Oct 2026)
Key ratios
- P/E ratio
- 0.5×
- Price / sales
- 1.7×
- Price / book
- —
- Free cash flow yield
- -450.3%
- Net margin
- 328.7%
- Operating margin
- -640.9%
- Return on equity
- —
- Liabilities / assets
- 105.9%
- Revenue growth
- +1113.0%
- R&D / revenue
- 435.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3M | +1113.0% | $-18M | $9M | 328.7% |
| Dec 2024 | $0M | 0.0% | $-142M | $-167M | -72400.0% |
| Dec 2023 | $0M | 0.0% | $-20M | $-19M | -8239.1% |
| Dec 2022 | $0M | 0.0% | $-20M | $-19M | -8243.5% |
| Dec 2021 | $0M | 0.0% | $-17M | $-16M | -7026.1% |
| Dec 2020 | $0M | -89.4% | $-25M | $-25M | -10939.1% |
| Dec 2019 | $2M | +77.2% | $-22M | $-22M | -986.2% |
| Dec 2018 | $1M | — | $-23M | $-21M | -1672.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-18M | $3M | $-21M | $0.82 | — |
| Dec 2024 | $-30M | $4M | $-33M | $-35.21 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-22.57 | — |
| Dec 2022 | $-16M | — | — | $-0.91 | — |
| Dec 2021 | $-19M | — | — | $-0.96 | — |
| Dec 2020 | $-23M | $0M | $-23M | $-2.17 | — |
| Dec 2019 | $-21M | $0M | $-21M | $-1.49 | — |
| Dec 2018 | $-23M | — | — | $-4.99 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportRegulation FD disclosure
- Oct 26, 2026S-1IPO registration
- Oct 23, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Oct 20, 2026DEF 14AProxy statement
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 31, 20268-KCurrent reportListing notice
- Jul 10, 20268-KCurrent reportOther events
- Jul 9, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 22, 20268-KCurrent reportRegulation FD disclosure
- Jun 12, 20268-KCurrent reportRegulation FD disclosure
- May 29, 2026DEF 14AProxy statement
Official filings of Traws Pharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $3 M
- Operating income
- $-18 M
- Net income
- $9 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $11 M
- Total equity
- $-1 M
As of December-2025
Top 33 institutional investors in Traws Pharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Orbimed Advisors LLC | 1,203,260 | 0 (0.00%) | 7.83% | $1 M | Nov 16, 2026 |
| 2 | Ally Bridge Group (NY) LLC | 786,236 | 0 (0.00%) | 5.12% | $0 M | Nov 16, 2026 |
| 3 | Adage Capital Partners GP, L.L.C. | 730,000 | 0 (0.00%) | 4.75% | $0 M | Nov 16, 2026 |
| 4 | ADAR1 Capital Management, LLC | 597,729 | 0 (0.00%) | 3.89% | $0 M | Nov 16, 2026 |
| 5 | Lynx1 Capital Management LP | 559,470 | 0 (0.00%) | 3.64% | $0 M | Nov 16, 2026 |
| 6 | Ikarian Capital, LLC | 478,142 | 0 (0.00%) | 3.11% | $0 M | Nov 16, 2026 |
| 7 | Sphera Funds Management LTD. | 398,486 | 0 (0.00%) | 2.59% | $0 M | Nov 16, 2026 |
| 8 | Citadel Advisors LLC | 205,680 | New | 1.34% | $0 M | Nov 16, 2026 |
| 9 | Alyeska Investment Group, L.P. | 164,376 | 0 (0.00%) | 1.07% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 152,849 | -177,200 (-53.69%) | 0.99% | $0 M | Nov 13, 2026 |
| 11 | Boothbay Fund Management, LLC | 133,936 | 0 (0.00%) | 0.87% | $0 M | Nov 16, 2026 |
| 12 | Geode Capital Management, LLC | 110,970 | -395 (-0.35%) | 0.72% | $0 M | Nov 6, 2026 |
| 13 | Kynam Capital Management, LP | 84,400 | 0 (0.00%) | 0.55% | $0 M | Nov 16, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 54,511 | 0 (0.00%) | 0.35% | $0 M | Nov 13, 2026 |
| 15 | HRT Financial LP | 50,102 | -41,118 (-45.08%) | 0.33% | $0 M | Nov 13, 2026 |
| 16 | Northern Trust Corp | 37,454 | 0 (0.00%) | 0.24% | $0 M | Nov 16, 2026 |
| 17 | Virtu Financial LLC | 28,732 | +16,153 (+128.41%) | 0.19% | $0 M | Nov 17, 2026 |
| 18 | State Street Corp | 25,802 | 0 (0.00%) | 0.17% | $0 M | Nov 12, 2026 |
| 19 | UBS Group AG | 19,616 | +16,165 (+468.41%) | 0.13% | $0 M | Nov 10, 2026 |
| 20 | Jane Street Group, LLC | 19,085 | -196,921 (-91.16%) | 0.12% | $0 M | Nov 12, 2026 |
| 21 | Susquehanna International Group, LLP | 15,837 | New | 0.10% | $0 M | Nov 16, 2026 |
| 22 | Citigroup Inc | 11,761 | New | 0.08% | $0 M | Nov 4, 2026 |
| 23 | StoneX Group Inc. | 11,106 | New | 0.07% | $0 M | Nov 3, 2026 |
| 24 | BlackRock, Inc. | 8,020 | -1,921 (-19.32%) | 0.05% | $0 M | Nov 13, 2026 |
| 25 | Tower Research Capital LLC (TRC) | 4,861 | -281 (-5.46%) | 0.03% | $0 M | Nov 16, 2026 |
Show all 33: investors 26 to 33
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Huntington National Bank | 4,675 | -1 (-0.02%) | 0.03% | $0 M | Nov 10, 2026 |
| 27 | SBI Securities Co., Ltd. | 1,723 | +2 (+0.12%) | 0.01% | $0 M | Oct 22, 2026 |
| 28 | Morgan Stanley | 837 | +369 (+78.85%) | 0.01% | $0 M | Nov 13, 2026 |
| 29 | Federation des caisses Desjardins du Quebec | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Vanguard Global Advisers, LLC | 262 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 31 | Northwestern Mutual Wealth Management Co | 5 | New | 0.00% | $0 M | Nov 13, 2026 |
| 32 | FMR LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 33 | Jones Financial Companies Lllp | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Traws Pharma, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 177,200 | $0 M | 1.2% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 152,849 | $0 M | 0.99% | <0.01% | +177% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 39,339 | $0 M | 0.26% | <0.01% | −4.2% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,098 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,466 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 743 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 321,970 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 365,661 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 104,398 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 33,198 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 21,108 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 23,169 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 14,441 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 11 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Traws Pharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | OrbiMed Capital GP VIII LLC10% owner | Buyindirect | +597,729 | $1.670 | $998 K | 1.20 M | Form 4 |
| filed | Charles Nolan ParkerChief Financial Officer | Grant or award | +15,393 | — | — | 15,393 | Form 4 |
| filed | Mary Teresa ShoemakerDirector | Grant or award | +6,157 | — | — | 6,292 | Form 4 |
| filed | Trafford ClarkeDirector | Grant or award | +6,157 | — | — | 6,157 | Form 4 |
| filed | Robert RedfieldChief Medical Officer | Grant or award | +16,419 | — | — | 113,919 | Form 4 |
| filed | John Harold LeamanDirector | Grant or award | +4,058 | — | — | 4,058 | Form 4 |
| filed | Charles David PauzaChief Science Officer Virology | Grant or award | +18,471 | — | — | 115,971 | Form 4 |
| filed | Nikolay SavchukChief Operating Officer, Director | Grant or award | +16,419 | — | — | 150,606 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Traws Pharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 1-for-14.93 reverse split ; 1-for-14.99 reverse split ; 1-for-10 reverse split ; 1-for-1.33 reverse split
Trading halts
- 2025-05-13 15:33 UTC, code LUDP, resumed 15:43 UTC
- 2024-12-27 15:03 UTC, code LUDP, resumed 15:08 UTC
- 2024-12-23 15:22 UTC, code LUDP, resumed 15:27 UTC
- 2024-12-23 15:12 UTC, code LUDP, resumed 15:17 UTC
- 2024-12-23 14:55 UTC, code LUDP, resumed 15:00 UTC
Fails to deliver
- : 3,911 shares at $0.30
- : 4,097 shares at $0.36
- : 56,722 shares at $0.37
- : 9,892 shares at $0.34
- : 15,169 shares at $0.34
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Traws Pharma, Inc. scorecard#
Passes 9 of the 17 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation3 of 4
- ✓P/E below its peers' median0.5×P/E 0.5× against Biotechnology's median of 17.5×.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✓Earnings yield above the 10-year Treasury yield200.0%Earnings yield 200.0% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- ✓Revenue up more than 5% a year over three years129.8%129.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median129.8%129.8% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year0.82 vs -35.21Diluted EPS 0.82 in fiscal 2025 against -35.21 the year before (report's currency).
- ✓Net income higher than five years earlier$9 M$9 M in fiscal 2025 against -$25 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability2 of 4
- ✓Profitable in the newest year$9 MNet income $9 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-640.9%-640.9% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-640.9%-640.9% in fiscal 2025 against -8534.8% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.72 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-89.77Z-score -89.77 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year439.3%Diluted shares up 439.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Traws Pharma, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -640.9% | -60.5% | |
| Net margin | 328.7% | -68.9% | |
| Revenue growth, 3 years a year | 129.8% | 12.9% | |
| Free cash flow margin | -744.1% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Free cash flow was negative: -$21 million.
- Only -198% of net income arrived as cash from operations.
- The share count rose 439.3% in the year.
- Shareholders' equity is negative: -$1 million.
Traws Pharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2.8+1135%100% | 0.20.0%100% | 0.20.0%100% | 0.20.0%100% | 0.2−2.2%100% | 0.2−89.4%100% | 2.2+77.8%100% | 1.2+56.0%100% | 0.8−85.8%100% | 5.5—100% | |
| Research and development | 12−5.5%435% | 13+12.4%5685% | 11+0.2%5058% | 11+56.3%5047% | 7.3−56.8%3229% | 17+8.8%7315% | 16−8.2%712% | 17−11.5%1378% | 19−4.7%2429% | 20—362% | |
| General and administrative | 8.5−30.7%305% | 12+35.1%5438% | 9.1+7.7%4024% | 8.4−10.4%3738% | 9.4+13.2%4170% | 8.3−0.2%3604% | 8.3+10.0%382% | 7.6+2.4%618% | 7.4−19.3%941% | 9.2—165% | |
| Operating expenses | 21−85.5%741% | 143+595%63097% | 21+3.4%9081% | 20+18.7%8785% | 17−33.7%7399% | 25+5.6%10919% | 24−2.6%1094% | 25−7.6%1996% | 27−9.3%3370% | 29—527% | |
| Operating income | −18—−641% | −142—−62997% | −20—−8981% | −20—−8685% | −16—−7299% | −25—−10819% | −22—−994% | −23—−1896% | −26—−3270% | −24—−427% | |
| Interest and finance income | 0.5−10.8%16.3% | 0.5−63.3%226% | 1.4+114%615% | 0.7—288% | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.5+65.4%17.1% | 0.3−78.6%128% | 1.4+104%597% | 0.7+5425%293% | 0.0−75.0%5.3% | 0.0−66.4%20.8% | 0.1−87.6%6.6% | 1.2+3737%93.7% | 0.0−51.6%3.8% | 0.1—1.1% | |
| Income before tax | 9.2—329% | −167—−73684% | −19—−8384% | −19—−8391% | −16—−7152% | −25—−10889% | −21—−985% | −21—−1672% | −24—−3060% | −20—−354% | |
| Income tax | — | — | — | — | — | 0.0−60.0%1.7% | 0.0—0.5% | −0.1−1054%−10.1% | 0.0−7.1%1.7% | 0.0—0.3% | |
| Net income including minority interests | 9.2—329% | −167—−73683% | −19—−8384% | −19—−8391% | −16—−7152% | −25—−10890% | −22—−985% | −20—−1662% | −24—−3061% | −20—−355% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | 0.2r−0.2—13.3% | — | — | |
| Net income attributable to shareholders | 9.2—329% | −167—−73683% | −19—−8384% | −19—−8391% | −16—−7152% | −25—−10890% | −22—−985% | −21—−1675% | −24—−3061% | −20—−355% | |
| Earnings per share, basic | 0.83—— | -35.21—— | -22.57r-0.90—— | -0.91—— | -0.96—— | -2.17r-0.14—— | -1.49—— | -4.99—— | -40.15r-2.68—— | -4.44—— | |
| Earnings per share, diluted | 0.82—— | -35.21—— | -22.57r-0.90—— | -0.91—— | -0.96—— | -2.17r-0.14—— | -1.49—— | -4.99—— | -40.15r-2.68—— | -4.44—— | |
| Shares, weighted average (basic) | 8.2+430%— | 1.6+84.9%— | 0.8r21−96.0%— | 21+24.2%— | 17+45.1%— | 12—— | — | — | — | — | |
| Shares, weighted average (diluted) | 8.4+439%— | 1.6+84.9%— | 0.8r21−96.0%— | 21+24.2%— | 17+45.1%— | 12r174−19.3%— | 14+249%— | 4.1+587%— | 0.6r9.0−86.4%— | 4.4—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.8−82.1%36.0% | 21+3.8%85.5% | 21−46.6%90.6% | 39−30.0%97.8% | 55+189%99.3% | 19−16.3%95.2% | 23+33.9%96.0% | 17+322%94.7% | 4.0−81.2%80.8% | 21—92.1% | |
| Receivables | 3.8+115%35.7% | 1.8+9706%7.1% | 0.0−37.9%0.1% | 0.0+3.6%0.1% | 0.0−24.3%0.1% | 0.0−62.2%0.2% | 0.1+180%0.4% | 0.0−40.7%0.2% | 0.1+90.3%1.2% | 0.0—0.1% | |
| Other current assets | 0.1−50.0%0.8% | 0.2−55.6%0.7% | 0.4+903%1.8% | 0.0+14.3%0.1% | 0.0−80.6%0.1% | 0.2+28.6%0.9% | 0.1+106%0.6% | 0.1−11.7%0.4% | 0.1+5.5%1.5% | 0.1—0.3% | |
| Current assets | 8.0−68.0%75.2% | 25+10.1%100.0% | 23−42.4%99.9% | 39−29.0%99.9% | 55+180%99.9% | 20−15.7%99.0% | 23+32.1%99.2% | 18+262%99.1% | 4.9−78.7%98.5% | 23—99.3% | |
| Property, plant and equipment | 0.0−30.0%0.1% | 0.0−54.5%0.0% | 0.0−8.3%0.1% | 0.0−36.8%0.1% | 0.0−26.9%0.1% | 0.1+4.0%0.3% | 0.1+456%0.2% | 0.0−85.9%0.1% | 0.1−57.9%1.3% | 0.2—0.7% | |
| Other intangible assets | 2.5—23.8% | — | — | — | — | — | — | — | — | — | |
| Total assets | 11−57.5%100% | 25+10.0%100% | 23−42.4%100% | 39−29.0%100% | 55+178%100% | 20−15.6%100% | 24+32.1%100% | 18+260%100% | 5.0−78.6%100% | 23—100% | |
| Accounts payable | 5.7−30.9%53.2% | 8.2+45.7%32.8% | 5.6+45.6%24.8% | 3.9+40.0%9.8% | 2.8−43.0%5.0% | 4.8+13.2%24.2% | 4.3+5.7%18.0% | 4.0−34.7%22.5% | 6.2+16.2%124% | 5.3—22.9% | |
| Current liabilities | 11−3.4%105% | 12+25.1%46.2% | 9.2+14.6%40.6% | 8.0+31.6%20.4% | 6.1−39.0%11.0% | 10+20.9%50.1% | 8.3−1.7%35.0% | 8.4−15.4%47.1% | 10.0−1.8%200% | 10—43.7% | |
| Total liabilities | 11−80.1%106% | 57+371%227% | 12+8.6%53.0% | 11+18.2%28.1% | 9.4−32.2%16.9% | 14+14.1%69.1% | 12−3.5%51.1% | 13−20.9%69.9% | 16−12.5%318% | 18—77.9% | |
| Retained earnings | −640—−6028% | −649—−2601% | −483—−2128% | −464—−1178% | −445—−802% | −429—−2144% | −403—−1704% | −382—−2131% | −362—−7277% | −338—−1456% | |
| Shareholders' equity | — | — | — | — | — | — | 12+115%48.9% | 5.4—30.1% | −12−372%−235% | 4.3—18.5% | |
| Minority interests | — | — | — | — | — | — | — | — | 0.80.0%16.7% | 0.8—3.6% | |
| Total equity | −0.6—−5.9% | −32−396%−127% | 11−62.3%47.0% | 28−38.6%71.9% | 46+647%83.1% | 6.2−46.6%30.9% | 12+115%48.9% | 5.4—30.1% | −11−312%−218% | 5.1—22.1% | |
| Total liabilities and equity | 11−57.5%100% | 25+10.0%100% | 23−42.4%100% | 39−29.0%100% | 55+178%100% | 20−15.6%100% | 24+32.1%100% | 18+260%100% | 5.0−78.6%100% | 23—100% | |
| Shares outstanding | 9.1+148%— | 3.7+334%— | 0.8r21−96.0%— | 21+0.1%— | 21+68.6%— | 12r186−88.8%— | 111+1859%— | 5.7+690%— | 0.7r11−89.4%— | 6.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1+408%2.2% | 0.0−25.0%5.3% | 0.0+14.3%7.1% | 0.00.0%6.2% | 0.0+7.7%6.2% | 0.0−7.1%5.6% | 0.0−74.5%0.6% | 0.1−37.5%4.5% | 0.1−8.3%11.2% | 0.1—1.7% | |
| Share-based compensation | 0.7−47.6%26.1% | 1.4+6.8%615% | 1.3+11.0%576% | 1.2+103%519% | 0.6+56.1%255% | 0.4−64.8%160% | 1.0−8.6%48.0% | 1.1−32.9%93.4% | 1.7−56.5%217% | 3.9—70.8% | |
| Cash from operating activities | −18—−652% | −30—−13182% | −18—−7935% | −16—−7210% | −19—−8623% | −23—−9989% | −21—−954% | −23—−1848% | −24—−3027% | −16—−285% | |
| Capital expenditure | −2.6—−92.7% | −3.6—−1614% | −0.0—−6.2% | — | — | −0.0—−6.5% | −0.1—−2.5% | — | — | — | |
| Cash from investing activities | −2.6—−92.7% | −3.6—−1614% | −0.0—−6.2% | — | — | −0.0—−6.5% | −0.1—−2.5% | — | — | — | |
| Shares issued | 5.6—200% | — | — | — | 55+507%24354% | 9.1−58.4%3923% | 22−38.0%997% | 35—2856% | — | — | |
| Cash from financing activities | 3.2−90.6%115% | 34—15034% | — | — | 56+187%24584% | 19−27.4%8380% | 27−25.3%1221% | 36+461%2904% | 6.4−63.5%808% | 17—314% | |
| Exchange-rate effect on cash | 0.0—1.7% | −0.0−290%−8.4% | 0.0—4.4% | −0.0—−8.4% | −0.0−188%−12.4% | 0.0—13.9% | −0.0—−0.3% | −0.0−144%−1.2% | 0.0—4.3% | −0.0—−0.2% | |
| Change in cash | −18−3488%−628% | 0.5—229% | −18—−7936% | −16−145%−7218% | 36—15949% | −3.7−164%−1602% | 5.8−55.5%264% | 13—1054% | −17−1188%−2214% | 1.6—28.9% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | 0*−100%— | 0*−100%— | 2.7+4695%100% | 0.1+1.8%100% | 0.1*0.0%100% | 0.10.0%100% | 0.1—100% | 0.1—100% | 0.1*—100% | 0.1—100% | |
| Research and development | 13+13.5%— | 1.1−51.9%— | 4.9+96.0%— | 5.0*+171%— | 2.3−54.8%— | 2.3−42.2%83.8% | 2.5+31.1%4396% | 1.9*−23.7%3318% | 5.1+108%8970% | 4.0—6954% | 1.9—3414% | 2.4*—4346% | 2.5—4316% | |
| General and administrative | 9.6−15.9%— | 3.5+106%— | 2.0−26.1%— | 2.3*−32.9%— | 1.7−49.9%— | 1.7−14.5%61.9% | 2.8−17.9%4832% | 3.5*+66.8%6207% | 3.5+29.6%6105% | 2.0—3468% | 3.4—5993% | 2.1*—3721% | 2.7—4712% | |
| Operating expenses | 22−7.0%— | 3.2−20.3%— | 6.9+32.1%— | 7.4*+38.1%— | 4.1−52.8%— | 4.0−96.8%146% | 5.3−0.2%9228% | 5.3*+18.1%9525% | 8.6+67.0%15075% | 123—216500% | 5.3—9407% | 4.5*—8068% | 5.1—9028% | |
| Operating income | −22—— | −3.2—— | −6.9—— | −7.4*—— | −4.1—— | −1.2—−45.7% | −5.2—−9128% | −5.3*—−9425% | −8.5—−14975% | −123—−216400% | −5.2—−9307% | −4.5*—−7968% | −5.1—−8928% | |
| Other non-operating income (expense) | 0.0−93.7%— | −0.1−150%— | −0.0−101%— | 0.0*—— | 0.1+57.4%— | 0.2−8.3%6.9% | 0.2−21.4%316% | −0.2*−174%−368% | 0.1−82.6%107% | 0.2—360% | 0.2—409% | 0.3*—496% | 0.4—614% | |
| Net income including minority interests | −22—— | −3.1*—— | −7.1−133%— | −7.4*—— | −4.0*—— | −0.9*—−33.5% | 21—37702% | −30*—−53432% | −8.5*—−14868% | −123*—−216040% | −5.0—−8898% | −4.2*—−7471% | −4.7—−8314% | |
| Net income attributable to shareholders | −22—— | −3.1—— | −7.1−133%— | −7.4*—— | −4.0—— | −0.9—−33.5% | 21—37702% | −30*—−53432% | −8.5—−14868% | −123—−216040% | −5.0—−8898% | −4.2*—−7471% | −4.7—−8314% | |
| Earnings per share, basic | — | -0.16—— | -0.53−124%— | — | -0.34—— | -0.11—— | 2.17—— | — | -1.49r-8.81—— | -20.52r-4.87—— | -5.92r-0.24—— | — | -5.64r-0.23—— | |
| Earnings per share, diluted | — | -0.16—— | -0.53−125%— | — | -0.34—— | -0.11—— | 2.09—— | — | -1.49r-8.81—— | -20.52r-4.87—— | -5.92r-0.24—— | — | -5.64r-0.23—— | |
| Shares, weighted average (basic) | 16+173%— | 16+173%— | 11+52.8%— | — | 8.8+817%— | 5.8+475%— | 7.0+728%— | — | 1.0+14.5%— | 1.0r25—— | 0.8r21—— | — | 0.8r21—— | |
| Shares, weighted average (diluted) | 16+173%— | 16+173%— | 11+47.5%— | — | 8.8+817%— | 5.8+475%— | 7.2+757%— | — | 1.0+14.5%— | 1.0r25—— | 0.8r21—— | — | 0.8r21—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5.0—43.7% | 5.0−61.7%43.7% | 3.1−80.3%38.4% | 3.8−82.1%36.0% | 6.4+18.7%51.6% | 13−22.5%83.7% | 16−2.8%83.6% | 21+3.8%85.5% | 5.4−78.6%60.5% | 17—90.4% | 16—90.2% | 21—90.6% | 25—93.4% | |
| Receivables | 3.5—30.1% | 3.5+161%30.1% | 1.7+2.0%20.7% | 3.8+115%35.7% | 2.0−6.1%16.0% | 1.3+7250%8.5% | 1.7+9089%8.7% | 1.8+9706%7.1% | 2.1+11683%23.7% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Other current assets | 0.1—0.8% | 0.1−25.0%0.8% | 0.1−24.6%1.7% | 0.1−50.0%0.8% | 0.1−73.5%0.7% | 0.1−78.7%0.8% | 0.2−30.4%1.0% | 0.2−55.6%0.7% | 0.3+14.5%3.9% | 0.6—3.1% | 0.3—1.4% | 0.4—1.8% | 0.3—1.1% | |
| Current assets | 9.0—78.7% | 9.0−41.3%78.7% | 5.7−70.0%69.5% | 8.0−68.0%75.2% | 9.6+7.9%77.4% | 15−17.7%98.4% | 19+3.9%98.9% | 25+10.1%100.0% | 8.9−67.0%99.9% | 19—99.9% | 18—99.9% | 23—99.9% | 27—99.9% | |
| Property, plant and equipment | 0.0—0.0% | 0.0−37.5%0.0% | 0.0−33.3%0.1% | 0.0−30.0%0.1% | 0.0−41.7%0.1% | 0.0−42.9%0.1% | 0.0−50.0%0.0% | 0.0−54.5%0.0% | 0.0−53.8%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Other intangible assets | 2.4—21.3% | 2.4—21.3% | 2.5—30.5% | 2.5—23.8% | 2.6—20.7% | — | — | — | — | — | — | — | — | |
| Total assets | 11—100% | 11−26.6%100% | 8.2−57.2%100% | 11−57.5%100% | 12+39.2%100% | 16−16.4%100% | 19+4.9%100% | 25+10.0%100% | 8.9−67.0%100% | 19—100% | 18—100% | 23—100% | 27—100% | |
| Accounts payable | 6.3—55.2% | 6.3+33.1%55.2% | 7.7+0.1%94.0% | 5.7−30.9%53.2% | 5.1−6.7%41.0% | 4.8−22.9%30.5% | 7.7+16.6%40.2% | 8.2+45.7%32.8% | 5.5−11.0%61.2% | 6.2—33.0% | 6.6—36.1% | 5.6—24.8% | 6.1—22.7% | |
| Current liabilities | 9.7—84.9% | 9.7+32.4%84.9% | 13+27.0%162% | 11−3.4%105% | 7.9−5.5%63.4% | 7.4−25.8%47.1% | 10+10.4%54.6% | 12+25.1%46.2% | 8.3−13.7%93.4% | 9.9—53.0% | 9.4—51.8% | 9.2—40.6% | 9.7—35.8% | |
| Total liabilities | 9.8—85.3% | 9.8+32.9%85.3% | 13+3.1%165% | 11−80.1%106% | 7.9−28.0%63.5% | 7.4−41.5%47.1% | 13+7.5%68.5% | 57+371%227% | 11−12.4%123% | 13—67.4% | 12—66.9% | 12—53.0% | 13—46.3% | |
| Retained earnings | −650—−5668% | −650—−5668% | −647—−7934% | −640—−6028% | −633—−5084% | −629—−4024% | −628—−3293% | −649—−2601% | −619—−6930% | −611—−3269% | −488—−2683% | −483—−2128% | −478—−1770% | |
| Total equity | 1.7—14.7% | 1.7−79.5%14.7% | −5.3−189%−65.1% | −0.6—−5.9% | 4.5—36.5% | 8.3—52.9% | 6.0−0.2%31.5% | −32−396%−127% | −2.0−114%−22.8% | −106—−565% | 6.0—33.1% | 11—47.0% | 15—53.7% | |
| Total liabilities and equity | 11—100% | 11−26.6%100% | 8.2−57.2%100% | 11−57.5%100% | 12+39.2%100% | 16−16.4%100% | 19+4.9%100% | 25+10.0%100% | 8.9−67.0%100% | 19—100% | 18—100% | 23—100% | 27—100% | |
| Shares outstanding | 15—— | 15+116%— | 10+100%— | 9.1+148%— | 7.1+136%— | 7.1−72.1%— | 5.1−75.9%— | 3.7+334%— | 3.0−85.6%— | 25—— | 21—— | 0.8r21—— | 21—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+2350%— | 0.0*+4300%— | 0.0+4300%— | 0.0*+2100%— | 0.0*+650%— | 0.0*−75.0%0.0% | 0.0−75.0%1.8% | 0.0*−50.0%3.6% | 0.0*−60.0%3.5% | 0.0*—7.0% | 0.0—7.1% | 0.0*—7.1% | 0.0*—8.8% | |
| Share-based compensation | 1.9+103%— | 0.8+677%— | 0.6+294%— | 0.3*−2.1%— | 0.1−60.6%— | 0.1−72.4%3.8% | 0.2−51.7%282% | 0.3*+0.6%596% | 0.3−4.7%602% | 0.4—667% | 0.3—595% | 0.3*—593% | 0.4—632% | |
| Cash from operating activities | −17—— | −7.5*—— | −2.6—— | −2.8*—— | −4.0*—— | −6.0*—−219% | −5.4—−9539% | −4.0*—−7214% | −11*—−20133% | −9.9*—−17284% | −4.4—−7900% | −4.4*—−7911% | −4.5*—−7840% | |
| Capital expenditure | — | — | — | 0*—— | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | — | |
| Cash from investing activities | — | — | — | 0*—— | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | — | |
| Shares issued | 4.2—— | 0.1*−96.3%— | 1.9+1455%— | 2.1*—— | 0.1*—— | 3.3*—119% | 0.1—214% | — | 0*—0.0% | — | — | — | — | |
| Cash from financing activities | 11−50.7%— | 9.4*+203%— | 1.9+14492%— | 0.2*−99.2%— | −0.1*—— | 3.1*—113% | 0.0—22.8% | 20*—35673% | 0*—0.0% | — | — | — | — | |
| Exchange-rate effect on cash | −0.0−133%— | −0.0*−111%— | −0.0−135%— | 0*—— | −0.0*—— | 0.0*—1.0% | 0.0—40.4% | −0.0*−229%−16.1% | 0*—0.0% | −0.0*—−5.3% | −0.0—−12.5% | 0.0*—12.5% | −0.0*—−3.5% | |
| Change in cash | −8.1—— | 1.9*—— | −0.7—— | −2.6*−116%— | −6.7*—— | −2.9*−676%−105% | −5.4—−9475% | 16*—28443% | −11*—−20133% | 0.5*—870% | −4.4—−7913% | −4.4*—−7898% | −4.5*—−7868% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Traws Pharma, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Single reportable segment$3 M100%+1113%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Traws Pharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 3 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 23, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2018 | $1 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Oct 2015 | $2 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Jul 2012 | $50 M | No. 4 | $50 to $250 million | 1 | equity | SEC |
| Apr 2012 | $26 M | No. 3 | $10 to $50 million | 41 | equity, options | SEC |
| Sep 2010 | $12 M | No. 2 | $10 to $50 million | 67 | equity | SEC |
| May 2009 | $19 M | No. 1 | $10 to $50 million | 58 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | · | 6 | · | · | · | · | · | 6 | · | · | · | · | 12 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 6 people (21% of workforce) | Restructuring planSEC 8-K | “The Company estimates the net reduction to be approximately 6 employees, which represents approximately 21 percent of its workforce.” | Filing | |
| 6 people (17% of workforce) | Restructuring planSEC 8-K | “The Company estimates the net reduction to be approximately 6 employees, which represents approximately 17 percent of its workforce.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Traws Pharma, Inc. compares in Biotechnology
- Market cap$5 M · higher than 5% of 726
- Revenue$3 M · higher than 32% of 647
- Revenue growth1113.0% · higher than 98% of 438
- P/E ratio0.5× · lowest of 100
- Price / sales1.6× · lower than 88% of 339
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Traws Pharma, Inc.🇺🇸 | $5 M | 0.5× | — | +1113.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Traws Pharma, Inc.? Verify and update this profile — free
Show Traws Pharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.